Dexamethasone in Cancer Surgery Boosts Survival Rates

Photo by Anna Shvets on Pexels

The survival of patients with breast, pancreatic and certain other cancers could be extended if given the anti-nausea drug dexamethasone during surgery. 

This finding comes from a large study being presented at the ANESTHESIOLOGY® 2021 annual meeting.

A drug with an already great range of uses including COVID treatment, dexamethasone is given to patients to prevent nausea and vomiting after surgery and during chemotherapy. Researchers found dexamethasone can improve mid- to long-term outcomes in patients with non-immunogenic cancers (those that don’t provoke a strong immune response) such as sarcoma and cancers of the breast, uterus, ovary, esophagus, pancreas, thyroid, bones and joints.

“Dexamethasone has positive and negative effects – it inhibits cancer growth, but also suppresses the immune system,” said senior author Maximilian Schaefer, MD, PhD. “Previous research has reported that in cancers in which the immune system controls cancer growth, the positive and negative effects of dexamethasone balance each other, so there is no benefit. Ours is the first large study to show that for a wide variety of cancers where the immune system does not play a major role, the positive effects seem to predominate.”

Researchers analysed the records of over 74 000 patients who had surgeries to remove non-immunogenic cancerous tumours, about a third of whom received dexamethasone during surgery. After 90 days, 209 (0.83%) of the patients who had received dexamethasone died vs 1543 (3.2%) of patients without the drug.

After accounting for confounding factors, including that dexamethasone is often administered to younger patients, there was still a 21% reduced risk of dying within one year after surgery for those who received the drug. It was also shown to be particularly beneficial for patients with cancers of the ovary, uterus or cervix.

“Based on our data, physician anesthesiologists should feel more confident in administering dexamethasone to patients undergoing surgery for non-immunogenic cancers,” said Dr Schaefer. “It not only helps with nausea, but it also may result in improved survival.”

Source: American Society of Anesthesiologists